The Trump administration yesterday ordered the National Institutes of Health to halt the use of human fetal tissue from elective abortions in NIH-funded research, a broad policy shift that officials say will speed a move toward lab-grown substitutes. NIH director Jay Bhattacharya has cast the change as a push to modernize biomedical science, but researchers warn it could bog down work on HIV, cancer, and brain development that depends on tissue scientists still cannot fully mimic in a dish.
What NIH announced
In yesterday's news release, the agency said federal NIH dollars will no longer support studies that use fetal tissue obtained from elective abortions and highlighted advances in organoids, tissue chips and computational biology as alternative tools, according to the National Institutes of Health. The statement emphasized that the new policy still allows older laboratory-adapted cell lines that were originally derived from fetal cells, and it said NIH will seek input on ways to cut back on the use of embryonic stem cells.
Scientists warn of setbacks
Researchers reacted strongly, arguing that fetal tissue is still essential for questions newer models cannot yet answer, as reported by The Washington Post. UCSF neuroscientist Tomasz Nowakowski told the paper that scientists critically need access to human brain tissue to study how the brain develops and to confirm that organoid models are actually accurate, and other experts cautioned that vaccine and therapeutic development could also slow under the new rules.
Policy details and who is affected
The formal grants notice states that the prohibition applies across NIH's Intramural Research Program as well as all extramural awards, overrides earlier guidance and takes effect as soon as the notice is published, according to NIH. The document says organizations with active awards may shift released funds into other allowable research and confirms that fetal tissue obtained from miscarriages or stillbirths can continue to be used under existing regulations.
Why fetal tissue is still used
Scientists and patient advocates point out that fetal tissue has long been central for modeling the human immune system, studying how the brain forms and testing vaccines and treatments in ways animal or engineered systems often cannot match, according to The Associated Press. The AP, citing NIH data, reports that the number of NIH-supported projects involving fetal tissue has declined since 2019, with 77 such projects listed in fiscal 2024.
Political roots and immediate fallout
The decision revives restrictions first put in place during Mr. Trump's initial term and later rolled back by the Biden administration, and it reflects a long-standing priority for anti-abortion groups, according to industry coverage. Fierce Biotech reports that the latest rule goes further than previous limits and has already sparked a wave of questions from laboratories and trade organizations about which projects will need to be reshuffled or shut down outright.
Next steps for researchers
NIH has said it will work with the scientific community and invite public comment on whether newer technologies can lessen or replace the need for human embryonic stem cells, according to The Associated Press. In the meantime, research institutions are weighing whether to rebudget grants, pause projects that require newly obtained fetal tissue or scramble to prove that alternative models can do the same job.
Local labs will feel the pinch
Researchers at major university medical centers told The Washington Post that Bay Area and Southern California labs reliant on NIH funding are already bracing for disruptions to long-running experiments and training pipelines. Fetal-tissue studies make up only a small fraction of the NIH portfolio, scientists note, but they say the biological insights are often outsized and that rebuilding those research capabilities, once lost, would require significant time and money.
